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The molecular basis for primary hereditary hypertriglyceridemia has been identified in fewer than 5% of cases. Investigation of mono-
genic dyslipidemias has the potential to expose key metabolic pathways. We describe a hitherto unreported disease in ten individuals
manifesting as moderate to severe transient childhood hypertriglyceridemia and fatty liver followed by hepatic fibrosis and the identi-
fication of the mutated gene responsible for this condition. We performed SNP array-based homozygosity mapping and found a single
large continuous segment of homozygosity on chromosomal region 12q13.12. The candidate region contained 35 genes that are listed in
Online Mendelian Inheritance in Man (OMIM) and 27 other genes. We performed candidate gene sequencing and screened both clin-
ically affected individuals (children and adults with hypertriglyceridemia) and also a healthy cohort for mutations in GPD1, which
encodes glycerol-3-phosphate dehydrogenase 1. Mutation analysis revealed a homozygous splicing mutation, c.3611G>C, which re-
sulted in an aberrantly spliced mRNA in the ten affected individuals. This mutation is predicted to result in a truncated protein lacking
essential conserved residues, including a functional site responsible for initial substrate recognition. Functional consequences of the
mutation were evaluated by measuring intracellular concentrations of cholesterol and triglyceride as well as triglyceride secretion in
HepG2 (hepatocellular carcinoma) human cells lines overexpressing normal and mutant GPD1 cDNA. Overexpression of mutant
GPD1 in HepG2 cells, in comparison to overexpression of wild-type GPD1, resulted in increased secretion of triglycerides (p ¼ 0.01).
This finding supports the pathogenicity of the identified mutation.Introduction
The two main sources of plasma triglycerides (TG) are
exogenous TG, absorbed in the gut and transported into
the plasma as chylomicrons, and endogenous TG, synthe-
sized in the liver and secreted as part of very-low-density
lipoprotein (VLDL) particles.1 Elevated TG levels may
represent primary hereditary disorders2,3 or be secondary
to other conditions, particularly obesity and type 2 dia-
betes mellitus.4–9 A molecular basis for primary hypertri-
glyceridemia has been identified in fewer than 5% of
cases.10 The study of monogenic dyslipidemias has the
potential to expose key pathways previously unrecog-
nized in lipid metabolism. An example includes auto-
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Severe monogenic hypertriglyceridemia can be seen
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protein lipase deficiency [MIM 238600] or from apo CII
deficiency [MIM 207750] or without fasting chylomicrone-
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of atherosclerotic plaques.12–14 Furthermore, several
studies indicate that hypertriglyceridemia is an indepen-
dent risk factor for coronary artery disease.14–18 Extreme
hypertriglyceridemia is also associated with an increased
risk of acute pancreatitis.19
Frequently, novel genetic diseases occur in families with
a high degree of consanguinity because this increases the
likelihood of identical-by-descent pathogenic mutations
as a result of inheritance from a common ancestor. Thus,
homozygosity mapping has become the most robust
strategy for the discovery of new genetic variants. In this
study we describe a hitherto unreported form of auto-
somal-recessive moderate to severe transient hypertrigly-
ceridemia in infancy and early childhood that is associated
with hepatic steatosis and the development of fibrosis.
Using homozygosity mapping, we identified a disease-
causing mutation, c.3611G>C [p.Ile119fsX94]), in
GPD1 (MIM 138420), which encodes glycerol-3-phosphate
dehydrogenase 1 (GPD1).Subjects and Methods
Affected Individuals
We identified four Israeli Arab families with a total of ten affected
family members (Figure 1A). In each of these families, there were
instances of both consanguineous and nonconsanguineous
marriages; however, all the families originate from the same iso-
lated population within a single village with a very high rate of
consanguinity. All the affected children presented in infancy
with similar clinical symptoms of the disease. We obtained
informed consent from all familymembers or their legal guardians
according to a protocol approved and reviewed by the Helsinki
committee of the Rabin Medical Center and in accordance with
a protocol approved and reviewed by the National Committee
for Genetic Studies, Israeli Ministry of Health.
For comparison, a group of white Canadian children (n ¼ 16,
age range 1 month to 18 years) with severe hypertriglyceridemia,
75 white adults with severe hypertriglyceridemia who had no
mutations in known genes, and 47 matched normolipidemic
Canadian controls were evaluated for sequence changes in GPD1.
The project had the approval of the office of research ethics,
University of Western Ontario, review number 07920E.
Homozygosity Mapping and Linkage Analysis
Genomic DNA for genotyping was extracted from peripheral
blood leukocytes in EDTA by standard procedures. SNP genotyp-
ing was performed on Affymetrix Human Mapping 250k NspI
arrays (Affymetrix, Santa Clara, CA, USA). All procedures and
methods were performed according to the manufacturers’ proto-
cols. The mapping data were analyzed with the Homozygosity
Mapper program.20
Sequencing of GPD1
Sequencing of the candidate gene was performed with primer sets
designed with the Primer3 program. All exons, including exon-
intron junctions, 50 UTRs, and 30 UTRs, were amplified from
genomic DNA with primers designed from the genomic sequences
available from the University of California-Santa Cruz (UCSC)
GenomeBrowser (assemblyhg19). Both strandsof thePCRproducts50 The American Journal of Human Genetics 90, 49–60, January 13, 2were sequencedwithBigDye Terminators onanABI 3100 sequencer
(Applied Biosystems, Foster City, USA). Sequence chromatograms
were analyzed with SeqScape software version 1.1 (Applied Bio-
systems). We initially sequenced the gene from one affected indi-
vidual and one heterozygous parent. Sequencing of genomic
GPD1 (NC_000012.11)wasperformedwitheightprimerpairs (Table
S1, available online). GPD1 mutation screening was performed on
genomic DNA by PCR amplification with primer 4F, 50-ACTT
GAGCTGGGTTGGAATG-30 (forward), and primer 4R, 50- GAGA
TGGCTAAGTGGGGTTG-30 (reverse), followed by sequencing.
GPD1 Mutation Detection by Restriction Analysis
Amplification of a 362 bp fragment from genomic DNA was
performed with primers GPD1-4F and 4R for nine cycles at an an-
nealing temperature of 64C and 26 cycles at an annealing temper-
ature of 55C. The mutation eliminates a DdeI restriction site that
digests the 362 bp fragment into 11, 119, and 232 bp pieces,
compared to a control sample, which digests into 11, 17, 119,
and 215 bp pieces. The fragment was digested with 2 U/mg DdeI
(New England Biolabs, Ipswich, MA, USA), and the products
were separated on 3% NuSieve/ 1% agarose gels.
Sequencing of GPD1 in Children and Adults with
Hypertriglyceridemia and Controls
The 16 Canadian children (described above) with severe hypertri-
glyceridemia (plasma TG range 1592-11,504 mg/dl [18 to
130 mmol/L]) were evaluated. In these individuals, previous
Sanger sequencing showed no mutations in LPL or APOC2, which
encode lipoprotein lipase and apolipoprotein C-II, respectively.
We also evaluated from a previously reported cohort21 75 white
adults with severe hypertriglyceridemia (mean plasma TG
1,239 mg/dl [14.0 mmol/L]) who had no mutations in known
genes, and 47 matched normolipidemic controls (mean plasma
TG 97 mg/dl [1.1 mmol/L]). Bidirectional Sanger sequencing of
GPD1 coding regions and intron-exon boundaries on genomic
DNAwas performed with the same primers on amodel 3730 Auto-
mated DNA Sequencer (Applied Biosystems, Mississauga, ON) at
the London Regional Genomics Centre (London, ON).
Bioinformatics Methods and Servers
GPD1 was described with the UCSC (February 2009 [GRCh37/
hg19]), NCBI (Build 37.1 [August 2009]) and Ensembl (February
2009 [GRCh37]) genome browsers. Evolutionary conserved
regions (ECR) browser analysis was performed on Human genome
(hg18) in order to show GPD1 genomic conservation.22 Pairwise
alignments were performed between human and various species,
including fugu pufferfish ([Takifugu rubripes], fr2), spotted green
pufferfish ([Tetraodon nigrovoridis] tetNig1), frog ([Xenopus laevis]
xenTro), chicken ([Gallus gallus] galGal), mouse ([Mus musculus]
mm9), rat ([Rattus norvegicus] rn4), dog ([Canis familiaris] can-
Fam), rhesus monkey ([Macaca mulatta] rheMac) and chimpanzee
([Pan troglodytes] panTro2).22 Structure information was obtained
from the PDBSum server,23 based on the crystal structure of
GPD1.24 Domain properties for GPD1 were obtained fromUniProt
server, Pfam database (PF) version 24.0 (10/2009),25 and InterPro
server (IPR).26 Information on protein expression was extracted
from the Bgee database.27
Plasmid Construction
RNA was extracted from the affected individual’s lymphoblastoid
cell line with Trizol reagent (Invitrogen Life Technologies,012
Figure 1. Family Tree, Candidate Region, and Mutation Analysis
(A) Pedigrees of the families and segregation analysis of themutation. Segregationwas assayed by PCR amplification of the genomic DNA
and restriction by DdeI. The mutation eliminates a DdeI restriction site, which digests the 362 bp fragment into 11, 119, and 232 bp
fragments, compared to a control sample, which digests into 11, 17, 119, and 215 bp. Blackened symbols represent affected individuals.
(B) Homozygosity region as defined by Homozygosity Mapper. Red lines represent the homozygosity region common to individuals
F2-III1 and F1-IV4.
(C) Candidate region (only OMIM genes listed).
(D) Mutation analysis of GPD1. Sequence chromatogram from wild-type (WT), carrier (C), and affected (M) genotypes on genomic DNA
and cDNA.Carlsbad, CA, USA) according to the manufacturer’s instructions.
Complementary DNA (cDNA) was synthesized with a High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems),
according to the manufacturer’s protocol. The wild-type human
GPD1 was cloned from a pDrive-hGPD1 full-length cDNA clone
(Openbiosystems, Huntsville, AL, USA) into pcDNA3.1 plasmids
with HindIII and XhoI sites. The mutated cDNA was amplified
with primers introducing the BamHI and NotI restriction sites,
respectively (underlined): forward: 50-GAGGATCCACCATGGCT
AGCAAGAAAG-30; reverse: 50-GCGCGGCCGCTCAGTGACCAGT
CACTGCT-30. The amplified fragment was digested with the
BamHI and NotI enzymes and subsequently ligated intoThe AmpcDNA3 plasmids, digested with the same enzymes, with T4
ligase (Promega, Madison, WI). The integrity of the plasmid
sequence was verified with direct DNA sequencing.
Normal and Mutant cDNA Transfection and
Expression in HepG2 Cells
To simulate the homozygous recessive state in vivo, we overex-
pressed mutant GPD1 cDNA in HegG2 cells, which presumably
results in the majority of GPD1 molecules being in the form ex-
pressed in the affected individuals. HepG2 cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) (Cellgro Medi-
atech, Manassas, VA, USA) with 10% FBS, 1 mM L-glutamineerican Journal of Human Genetics 90, 49–60, January 13, 2012 51
Table 1. Clinical Characteristics of the Affected Individuals
F1-IV1 F1-IV2 F1-IV4 F2-II6 F2-III1 F3-V1 F3-V2 F3-V3 F4-II4 F4-III3
Birth (week) NA NA 36 NA 40 42 37a 37a 34a 34a
Birth weight
(grams)
3,000 NA 2,180 3,395 2,570 3,000 2,430 2,190 1,950 2,160
Presenting signs
and symptoms
V HM, V HM HM HM, FTT HM, V HM HM HM LFT
Presenting age
(months)
1 1 4–6 Birth 6 2.5 7 7 9 3.5
Liver size at
presentation (cm)
NA NA 6–7 BCM 6–7 BCM 12 S 4 BCM 8 BCM 10 BCM 7 BCM 4b BCM
Spleen at
presentation (cm)
BCM
NA NA 0 3 NA 0 2 4–5 0 0
Age at last exam
(years)
14.2 9.8 11.9 23 2.9 4.3 1.3 1.3 12.2 11
Height (cm) at
last exam (SDS)
161
(0.50)
127
(1.65)
126.5
(3.05)
160
(2.34)
84.5
(1.94)
100
(0.59)
77
(0.30)
74
(1.25)
130.8
(2.70)
129
(2.13)
Weight at last
exam (SDS)
65.5
(1.14)
22.5
(2.28)
25.8
(2.66)
58.5
(0.93)
12.3
(0.75)
16.5
(0.06)
9.3
(1.16)
8.2
(2.44)
26.5
(2.75)
25.6
(2.14)
Liver at last
exam (cm)
4 S 5 S 12 S 15 S 13 S 3–4 BCM 9.5 S 11 S NA NA
The following abbreviations are used: BCM, below costal margin; FTT, failure to thrive ; HM, hepatomegaly; LFT, elevated liver enzymes; NA, not available; S, span;
SDS, standard deviation score; Centers for Disease Control (CDC) 2000 (see Web Resources); V, vomiting.
a Twin.
b At 1.5 years of age.and 1% pen/strep and incubated at 37C in a 5% CO2 incubator.
The cells were transiently transfected with pcDNA3.1-hGPD1
wild-type or pcDNA3.1-hGPD1 mutant constructs in Opti-MEM
(Invitrogen, Camarillo, CA, USA) with FuGENE HD Transfection
Reagent (Roche, Indianapolis, IN, USA), according to the manu-
facturer’s protocol. Forty-eight hours after transfection, cellular
lipids were extracted and total cholesterol and TG were quantified
enzymatically with Cholesterol E and L-Type TG M kits (Wako
Diagnostics, Richmond, VA, USA). For measurement of the TG
secretion, HepG2 cells were washed twice with cold PBS and incu-
bated with serum-free medium for 6 hr. The concentration of the
secreted TG in the medium was quantified fluorometrically at Ex/
Em 530 nm/590 nm with a TG quantification kit (BioVision,
Mountain View, CA, USA). The results were normalized to the
total protein, which was measured with the Bio-Rad Dc protein
assay.Results
Clinical and Laboratory Evaluation
Allof theaffected individualspresentedbetween theagesof1
and 9 months. Their clinical characteristics are shown in
Table 1. The presenting complaints included vomiting
(n ¼ 3), poor weight gain (n ¼ 1), and asymptomatic
(n ¼ 6). On initial examination they had moderately to
severely enlarged livers, and three had mild to moderate
splenomegaly. Fasting hypertriglyceridemia was universally
present, ranging from mild to severe (TG 258–6,244 mg/dl
[2.91–70.6 mmol/l] normal 50–150 mg/dl), as were
elevated transaminases and gamma-glutamyl transferase52 The American Journal of Human Genetics 90, 49–60, January 13, 2(GGT). Bilirubin and synthetic liver function (coagulation
studies and albumin) were within normal limits at presen-
tation and throughout the follow-up period (Table 2).
Cholesterol levels were normal in all but one of the infants
(whose levels normalized during follow-up). Of note, all of
those in whom liver enzymes (F1-IV4, F4-III3, F4-II4) and
TG (F1-IV4) were examined at birth had normal levels
and a liver with a normal span. Sonographic findings
compatible with fatty liver were present in eight of the
ten affected individuals at presentation, and the remaining
two developed similar findings at 1 year of age. These
included diffuse hyperechogenicity of the liver paren-
chyma with a fine granular pattern and, in some affected
individuals, loss of portal spaces (Figures 2E–2F). None
have yet developed cutaneous xanthomas. Fasting hypo-
glycemia was not present. Individual F4-III3 has the addi-
tional diagnoses of infantile intraventricular hemorrhage,
transverse sagittal sinus thromboses, decreased protein C,
celiac disease, epilepsy, acquired microcephaly, and
communicating hydrocephalus with a ventriculo-perito-
neal shunt. At the time of his hemorrhage, he had episodes
of severe hyperglycemia (over 1,000 mg/dl), which did not
recur at other times of stress or illness. In addition, he had
mildly and intermittently elevated pyruvic acid and
moderate elevations of ammonia. This affected individual
is the twin of affected individual F4-II4, who has
a horseshoe kidney, and they have another sibling who
has the CHARGE association (coloboma, heart defects,
atrasia choanae, retarded growth/development, genital,012
Table 2. Laboratory Testing Results
Affected
Individual
Age at Initial
Tests (Months)
Age at Last
Tests (Years)
Initial TGa
(mg/dl)
Last TGa
(mg/dl)
Initial Cholesterol
(mg/dl)
Last Cholesterol
(mg/dl)
Initial ALT
(U/l)
Last ALT
(U/l)
F1-IV1 1 13.7 6,244 250 420 73 230 39
F1-IV2 1 9.9 250 247 109 207 115 81
F1-IV4 6 11.9 990 289 164 172 83 37
F2-II6 0.25 23 520 170 101 114 109 79
F2-III1 6 2.9 1,208 202 109 184 125 70
F3-V1 2.5 4.3 349 135 66 202 155 29
F3-V2 7 1.3 258 185 95 118 51 38
F3-V3 7 1.3 330 202 99 141 94 71
F4-II4 9 12.5 225 301 106 188 132 93
F4-III3 3.5 12.5 566 434 149 256 90 165
Values in bold are elevated beyond normal values for age. 1 mg/dl TG¼ 0.0113 mmol/l (normal 10–150 mg/dl); 1mg/dl cholesterol ¼ 0.0259 mmol/l (normal <
170 mg/dl, borderline 170–200 mg/dl). Normal ALT 7–50 U/l up to 6 months and 7–35U/l beyond 6 months.
a Fasting TG levels.ear abnormalities). Besides this individual and one other
who had transient hypotonia of infancy that later
resolved, all others had normal neurologic findings
throughout their follow-up including muscle tonus and
motor development, and all have physical capabilities
compatible with their respective ages.
In-depth studies were performed. These produced
normal results and included infectious serologies (hepatitis
A, B, and C viruses, Epstein-Barr virus [EBV], cytomegalo-
virus [CMV], human immunodeficiency virus [HIV] [three
examined], toxoplasma [five examined]), thyroid studies,
alpha-1 anti-trypsin levels, galactose 1 phosphate uridyl
transferase activity, serum amino acids, ferritin, creatine
phosphokinase, alpha-fetoprotein (high in one individual
at 3 months, normalized at 3 years), albumin, smooth-
muscle antibody, anti liver-kidney microsomal antibody,
nuclear antibody (elevated in one affected individual),
mitochondrial antibody, sweat test, vertebral X-rays,
immunoglobulin levels, and glycogen storage diseases 3
and 6. Apolipoproteins A1, B, C2, and C3 levels, and apo
E genotype were measured in six affected individuals.
The samples were drawn in all but one affected individual
when TG levels were either normal or only mildly elevated
(after the GPD1mutation was identified). In the individual
with severely elevated TG (1,250 mg/dl), apo C2 and apo
C3 were elevated to 12.2 and 42.2 mg/dl, respectively
(normal apo C2, 3–7 mg/dl; apo C3 9–19 mg/dl). One indi-
vidual with mild hypertriglyceridemia (293 mg/dl) had
elevated apo C3 (25 mg/dl), and one affected individual
with normal TG (163 mg/dl) had low levels of apo C2
(1.8 mg/dl) and apo C3 (7.0 mg/dl). High-density lipopro-
tein-calculated levels were, not surprisingly, low at early
ages and increased to normal levels over time. Interest-
ingly, five of nine affected individuals for whom urinary
organic acid profiles were available had mildly elevated
fasting urinary dicarboxylic acids with a nonspecificThe Ampattern. Of these, two had elevated and two decreased
ketones. Dicarboxylic aciduria decreased as the affected
individuals’ age increased. Lactate levels were normal,
pyruvate was borderline in three, and ammonia elevated
only in individual F4-III3, who had several additional diag-
noses, as described above. In order to further investigate
a possible derangement of beta-oxidation or a more
general mitochondrial or peroxisomal disorder, acyl-carni-
tine profiles and free fatty acids were measured in six
affected individuals and very-long-chain fatty acids in
five. All were found to be normal.
Although transaminases normalized in four, the
majority had elevated liver enzymes at the time of their
last clinical evaluation. Triglyceride levels decreased in
eight individuals; however, in seven the levels were still
above 200 mg/dl. Total cholesterol levels increased moder-
ately in nine individuals, but remained within normal
limits in all but three (Table 2). The oldest affected indi-
vidual, F2-II6, 23 years of age at the last follow-up, remains
asymptomatic, with short stature, elevated transaminases,
and a hyperechoic liver compatible with fatty change.
None of the heterozygous parents or siblings examined
had elevated TG or transaminases except for one morbidly
obese mother who had elevated triglycerides without find-
ings compatible with hepatic steatosis on ultrasound. The
heterozygous mother of affected individual F2-II6 (grand-
mother of affected individual F2-III1) had a mild fatty liver
on ultrasound at 47 years of age and normal liver function
tests. One family had a history of early cardiovascular
disease.
Two individuals, F1-IV4 and F1-IV2, underwent liver
biopsies at 4.5 and 2.5 years, respectively. The biopsies
demonstrated marked mixed macro- and microsteatosis
with fibrosis and septal formation. Both had mild inflam-
matory infiltrates; in one there was a mixed infiltrate,
whereas in the other it was mononuclear (Figure 2). Fourerican Journal of Human Genetics 90, 49–60, January 13, 2012 53
Figure 2. Liver Biopsies and Ultrasound
(A and B) Affected individuals F1-IV2 at 2.4 years
of age: Trucut liver biopsy. (A) The liver paren-
chyma shows macro- and microvesicular fatty
change and mild mononuclear inflammatory
infiltrate in the portal spaces. Hematoxylin and
eosin staining (H&E), magnification 103. (B)
Widening of the portal spaces because of fibrotic
deposition with septal formation. Masson tri-
chrome stain, magnification 103.
(C and D) Affected individual F1-IV4 at 4.5 years
of age: Trucut liver biopsy. (C) Liver parenchyma
shows fatty change, both macro- and microvesic-
ular, and small collections of inflammatory cells,
including lymphocytes, histiocytes, polymor-
phonuclears, and eosinophils. H&E, magnifica-
tion 103. (D) Portal fibrosis with septal formation
and mild sinusoidal fibrosis. Masson Trichrome
stain, magnification 103.
(E) Ultrasound of affected individual F1-IV4 at
11.9 years of age demonstrates diffuse hyperecho-
genicity of the liver with a fine granular pattern.
In comparison, the kidney parenchyma (K)
appears hypoechoic.
(F) Ultrasound of another affected individual at
3 months of age showing dense diffuse hypere-
chogenicity of the liver with loss of imaging of
the portal areas.affected individuals have short stature (height standard
deviation score < 2 standard deviation).
Mapping of the Candidate Region to 12q13.12
Visual inspection of the SNP data and homozygosity anal-
ysis with Homozygosity Mapper showed that the two
affected individuals initially examined, F2-III1 and
F1-IV4, exhibited a single large continuous segment of
homozygosity on 12q13.12 for 163 consecutive SNPs
between markers rs11168871 and rs7313454, encompass-
ing2.9Mb (Figure 1B). These datawere supportive ofhomo-
zygosity by descent. There were no additional significant
regions of homozygosity. The candidate region contained
35 genes that are listed in Online Mendelian Inheritance
in Man (OMIM) and 27 other genes (Figure 1C).
Mutation Analysis
Because GPD1 is known to be associated with glycerol
metabolism, it was prioritized as a candidate for
sequencing because we thought it was the most likely
gene to be mutated in the affected children.
Sequencing of GPD1 revealed a splice-site mutation in
intron 3, c.3611G>C, at coding sequence position 360
(NM_005276.2, according to Recommendations for the
Description of DNA Sequence Variants [Ensembl Genome
Browser]) (Figure 1D). The normal transcript is composed54 The American Journal of Human Genetics 90, 49–60, January 13, 2012of eight coding exons. The resulting
mutated transcript is predicted to consist
of the first three exons (360 bps, 120 amino
acids) and an addition of 279 bps (93 amino
acids) translated from intron 3, creatinga mutated protein of 213 residues: c.3611G>C
(p.Ile119fsX94) (ss472336569) (Figure 3). The mutation
segregates with the disease; affected individuals displayed
homozygousmutations, whereas parents displayed hetero-
zygosity for a normal and a disease allele, consistent with
autosomal-recessive inheritance (Figure 1A). The mutation
was not observed in 404 chromosomes from unrelated
control individuals of Arab origin and 94 chromosomes
of non-Arab origin.
Bioinformatics Analysis
Pairwise alignments are shown between human and
various species as described in the methods section
(Figure 4). The human and chimpanzee proteins are iden-
tical (99% at the nucleotide level), whereas the mouse
protein shared 96% identity to human (NCBI UniGene
Hs.524418). Human GPD1 resides within chromosomal
region 12q12-q13 (50,497,801–50,505,096; 7,296 bps;
RefSeq: NM_005276.2). The mRNA consists of 2,909 bps,
including eight exons, all coding. The open reading frame
size is 1,050 bps encoding a protein of 349 residues
(NP_005267.2; P21695; GPDA_HUMAN), (Uniprot data-
base) (Figures 4B and 4C). GPD1 consists of two
domains: NAD_Gly3P_dh_N (PF01210; IPR011128) and
NAD_Gly3P_dh_C (PF07479; IPR006109) (Figure 4C).
The Homo sapiens GPD1 (Enzyme Commission numberEC
Figure 3. cDNA Analysis of Splice-Site Modifi-
cation in an Affected Individual and Control
Splice-sitemutation eliminating the exon 4 splice
site and creating a shorter protein by translation
continuation from the mutation site until
a stop codon in-frame.1.1.1.8) belongs to the NAD-dependent glycerol-3-phos-
phate dehydrogenase family; it is soluble and is found in
the cytoplasm. The protein has been cloned from the
human liver.28 GPD1 catalyzes the reversible redox reac-
tion of dihydroxyacetone phosphate (DHAP) and nicotine
adenine dinucleotide, reduced (NADH) to glycerol-3-phos-
phate (G3P) and nicotinamide adenine dinucleotide
(NADþ) and together with a mitochondrial enzyme, glyc-
erol-3 phosphate dehydrogenase 2 (GPD2), plays an
important role in the transport of reducing equivalents
from the cytosol to the mitochondria. The crystal structure
of GPD1 has been delineated;24 it shows a secondary struc-
ture with various active sites in addition to a relatively
conserved C terminal (Figure 4B). The key residue for
initial recognition of the substrate (Arg269) has been iden-
tified.24 GPD1 is expressed in a variety of tissues, including
various regions of the brain, internal tissues, and many
other tissues and is found in all the human developmental
stages (Bgee database).27 In pigs, mesentery fat, subcuta-
neous fat, and duodenum demonstrate the highest levels
of expression of GPD1; liver, kidney, cerebellum, ileum,
and latissimus dorsi muscle have intermediate levels,
whereas the heart, pancreas, spleen, jejunum, and cere-
brum exhibit the lowest levels.29 The mutated protein is
predicted to be truncated, missing section of the protein
containing essential components, including major
secondary structures and essential conserved residues,
some of them known as active sites (Figure 4B).24 More-
over, themutated protein has acquired 93 new amino acids
that do not show any ordered domains.Evaluation of Children and Adults with
Hypertriglyceridemia
Several common and rare variants of GPD1, both synony-
mous and nonsynonymous, were found in both cases and
controls from the Canadian cohort (Table 3). Most of these
have been previously reported in normal populations. No
variant differed in frequency between cases and controls.Evaluation of the Functional Consequences
of the Mutation
In order to evaluate the consequences of the GPD1 muta-
tion found in affected individuals, we cloned both wild-
type and mutant GPD1 cDNA, transfected HepG2 cells,The American Journal ofand measured intracellular concentrations
of cholesterol and TG as well as TG secre-
tion into supernatant by HepG2 cells. By
overexpressing either the mutant or wild-type allele, we simulated the homozygous recessive state
in vivo. Overexpression of mutantGPD1 in a human hepa-
tocellular carcinoma-derived HepG2 cell line resulted in
increased secretion of TG into the medium (~33%)
compared to cells overexpressing the wild-type GPD1
(Figure 5) (1.27 nM/mg protein versus 0.96 nM/mg
protein, p ¼ 0.01). Intracellular TG and cholesterol levels
were also higher (~10% and ~20%) in cells overexpressing
mutantGPD1; however, these changes did not reach statis-
tical significance (Figure 5) (p ¼ 0.2 and 0.7, respectively).Discussion
In this study we show that a mutation in GPD1 is associ-
ated with moderate to severe transient hypertriglyceride-
mia in infancy and early childhood that normalizes with
age. The presence of an identical mutation in several fami-
lies originating from the same village supports the pres-
ence of a founder effect in this isolated population. This
is not surprising because the consanguinity rate within
this specific population is high and affected individuals
belong to only three large interrelated clans. The hypertri-
glyceridemia is associated with hepatomegaly and moder-
ately elevated transaminases that may decrease later in
life, persistent fatty liver, and the development of hepatic
fibrosis. Serum TG levels are variable and could normalize
during childhood or through adolescence.
The availability of G3P has been considered a possible
regulatory factor in the synthesis of TGs.30 It has been
shown that the level of G3P in isolated hepatocytes from
starved rats and glycogen-depleted hepatocytes from fed
rats was low and severely limited TG synthesis. Raising
the G3P level by the addition of precursors resulted in
a hyperbolic-like relationship between TG synthesis and
the cellular G3P level.30 Despite the essential role of the
enzyme in carbohydrate and lipid metabolism, no human
diseases have yet been reported to be caused by mutations
in GPD1.
The G3P shuttle is used to rapidly regenerate NADþ in
the brain and skeletal muscle of mammals. Once G3P has
passed through the inner mitochondrial membrane, it
can be oxidized by a separate isoform of glycerol-3-phos-
phate dehydrogenase encoded by GPD2. Mitochondrial
GPD2 is located on the outer surface of the innerHuman Genetics 90, 49–60, January 13, 2012 55
Figure 4. GPD1 Gene Evolutionary Conservation and Protein Structure
(A)GPD1 gene evolutionary conservation presented by ECR browser. Sequence conservation of exons (blue) and introns (orange), as well
as UTR (yellow) and repeats (green) can be visualized. Layer height presents % identity of sequence pairwise alignment, asterisk and red
vertical line represent the location of the mutation.
(B) Protein ‘‘wiring diagram’’ of GPD1. This schematic plot provides sequence, secondary structure elements, domains and motifs. The
splicing point is marked on the protein’s secondary structure (red asterisk). The protein sequence is colored by conservation (high
sequence conservation is marked in red, low conservation in blue). Secondary structures (helices (H1-H18) and strands) are marked
in purple. Legend key presents motifs, patterns and active sites (colored triangles) on the protein.
(C) GPD1 Domains. Two GPD1 Domains from Pfam are shown. The mutation is marked by a red asterisk.mitochondrial membrane and catalyzes the unidirectional
conversion of G3P to DHAP with concomitant reduction
of the enzyme-bound FAD. Together with a cytosolic
GPD1, GPD2 forms the glycerol phosphate shuttle, which
uses the interconversion of G3P and DHAP to transfer
reducing equivalents into mitochondria, resulting in the
reoxidation of NADH formed during glycolysis. It is
unknown whether mitochondrial NADH can drive lipid
synthesis. Nevertheless, it should be mentioned that the
affected individuals whom we studied show no clinical
or laboratory evidence of mitochondrial disease or
muscular weakness.
In our study we show that a mutation in GPD1 leads to
severe but transient hypertriglyceridemia, possibly by
limiting the conversion of G3P to DHAP, and thus causing
an increase in the amount of hepatic G3P available for TG56 The American Journal of Human Genetics 90, 49–60, January 13, 2synthesis. Alternatively, another intriguing theory is that
because under physiological conditions GPD1 is oriented
toward the conversion of DHAP to G3P, it is possible that
accumulation of DHAP could lead to the overproduction
of methylglyoxal, an alpha-ketoaldehyde and dicar-
bonyl,31 which can behave as a highly toxic compound
at the cellular level and which has been associated with
renal fibrosis in diabetic patients.32
The transient nature of the hypertriglyceridemia in the
individuals described in this study is compatible with the
fact that the rates of TG secretion by hepatocytes are
higher in neonates than in adults, as shown by Waterman
et al.33 in hepatocytes from rat livers of different ages. In
addition, hepatic TG concentrations in rat liver are known
to increase rapidly within the first 24 hr after birth and to
decrease to adult values by the 10 days of age, whereas012
Table 3. GPD1 Variants Detected in Canadian Affected Individuals
Variant Name
Allele Frequency
Pediatric
Hyperchylomicronemia
(N ¼ 16)
Adult Severe
Hypertriglyceridemia
(n ¼ 75)
Adult Controls
(n ¼ 47)
Intron 1 þ43C>G (ss475871079) (NM_005276.2:c.74þ43C>G) 0.0 0.007 0.0
Intron 2 þ20G>A (ss475871080) (NM_005276.2:c.252þ20G>A) 0.0 0.0 0.011
p.I54V (rs2232202) (NM_005276.2:c.193A>G) 0.032 0.0 0.0
Intron 3 114G>A (rs2232203) (NM_005276.2:c.394-114G>A) 0.0 0.027 0.064
Intron 3 73G>A (rs2232204) (NM_005276.2:c.394-73G>A) 0.0 0.040 0.064
Intron 3 56G>A (rs2232205) (NM_005276.2:c.394-56G>A) 0.0 0.040 0.021
p.E124K (rs34783513) (NM_005276.2:c.403G>A) 0.0 0.007 0.011
p.V197A (rs2232207) (NM_005276.2:c.623T>C) 0.032 0.0 0.0
p.K204K (rs35256655) (NM_005276.2:c.645G>A) 0.0 0.007 0.0
p.V206V (ss475871081) (NM_005276.2:c.651A>T) 0.0 0.007 0.0
p.T223I (ss475871082) (NM_005276.2:c.701C>T) 0.0 0.0 0.011
p.A225A (ss475871083) (NM_005276.2:c.708G>A) 0.0 0.0 0.011
p.A278A (ss475871084) (NM_005276.2:c.867G>A) 0.0 0.007 0.0
Intron 6 þ10G>A (ss475871085) (NM_005276.2:c.879þ10G>A) 0.0 0.0 0.011
p.I339I (rs836180) (NM_005276.2:c.1050C>T) 0.219 0.380 0.361
30UTR þ99C>T (ss475871086) (NM_005276.2:c.1083þ99G>A) 0.0 0.007 0.0plasma TG concentration is low in the newborn rat and
rises rapidly to reach a peak value by 9 days of age, and
there are no further changes until 21 days.34 After wean-
ing, the rat plasma TG concentration decreases gradually.
The decrease in plasma TG concentration after several
months of age in the individuals described here may be
consistent with the observations in rats, although changes
in dietary intake are another possible explanation.
gpd1 delta mutants in Saccharomyces cerevisiae produce
very little glycerol, and they are sensitive to osmotic
stress.35 Mice showing loss of glycerol-3-phosphate dehy-
drogenase activity in adult tissues have normalmorpholog-
ical, physiological, and reproductive characteristics,36 but
in mice carrying ~25 copies of Gpd1, the amount of brown
fat is greater than that in nontransgenic littermate controls.
Glycerol 3-phosphate dehydrogenase activity in adipose
tissue frommorbidly obese subjects is approximately twice
as high as it is in that from lean individuals.37 Moreover,
a positive correlation between adipose tissue glycerol
3-phosphate dehydrogenase activity and body mass index
has been found. These data indicate that elevated glycerol
3-phosphate dehydrogenase might contribute to the
increase of TG synthesis in obese subjects. In this study
we show that, on the contrary, defective GPD1 activity
causes severe hypertriglyceridemia leading to fatty liver. It
is of note that the affected individuals described in this
study have normal body mass indices, refuting the role of
obesity in the pathophysiology of the development of
hepatic steatosis in these individuals.The AmOur findings in HepG2 cells support the observation
that the mutation causes increased TG synthesis and
secretion levels. This in itself may explain the develop-
ment of increased plasma TG levels, as well as fatty liver,
in affected individuals, though other mechanisms related
to the role of the enzyme in glyceroneogenesis38 or oxida-
tive phosphorylation could play a role in liver fat accu-
mulation.
The pathophysiology of hepatosteatosis is not clear but
could involve increased influx of fatty acids into the liver,
decreased TG export from the liver, and impaired hepatic
beta-oxidation and cellular energy homeostasis. Indeed,
multiple factors may play substantial roles simultaneously.
The molecular mechanisms that link steatosis to fibrosis
and cirrhosis have yet to be clearly delineated. Nonalco-
holic fatty liver disease (NAFLD) is usually related to dia-
betes mellitus, obesity, and hyperlipidemia and is the
hepatic component of the metabolic syndrome.39 It is
also part of other lipid disorders (abetalipoproteinemia),
infectious diseases (hepatitis C), disorders involving carbo-
hydrate metabolism (glycogen storage diseases, hereditary
fructose intolerance, galactosemia), protein metabolism
(homocystinuria, tyrosinemia), as well as disorders of the
mitochondria and oxidative phosphorylation.40 Although
NAFLD can be a relatively benign disease in many affected
individuals, cirrhosis might develop in 20% of those
affected.39 Thus the development of hepatic fibrosis in
affected individuals might be the result of the fat accumu-
lation in liver tissue. However, specific triggers related toerican Journal of Human Genetics 90, 49–60, January 13, 2012 57
Figure 5. Intracellular and Secreted TG and Total Cholesterol Concentration in HepG2 Cells Overexpressing Wild-Type and Mutant
GPD1 cDNA
(A) Total cholesterol content in wild-type and mutant GPD1 overexpressing Hep2G cells.
(B) TG content in wild-type and mutant GPD1 overexpressing HepG2 cells.
(C) TG accumulation in medium in wild-type and mutant GPD1 overexpressing HepG2 cells.
Error bars represent standard error of the mean.the mutation inGPD1 cannot be excluded and will need to
be sought in the future.
It is important to emphasize that no clinical evidence of
coronary heart disease or episodes of recurrent pancreatitis
have been observed in the oldest individual (aged 23
years). However, most affected individuals evaluated in
this study are young, and no conclusions can be drawn
at this point about the influence of severe childhood hy-
pertriglyceridemia on the risk for coronary heart disease
or about the effect of this mutation on longevity. Heterozy-
gous family members do not have recorded increased TG
levels or hepatomegaly in childhood, nor do they have
biochemical evidence of hepatic dysfunction. Long-term
follow-up of both affected individuals and heterozygotes
will help to clarify the issue of any long-term morbidity
associated with the mutation.
In summary, we have demonstrated that a GPD1 muta-
tionmay be responsible for moderate to severe hypertrigly-
ceridemia and fatty liver in early infancy followed by
reduction and even normalization of TG serum levels later
in life, but with sustained liver dysfunction and progres-
sion of the fatty liver to fibrosis.Supplemental Data
Supplemental Data includes one table and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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